Posted by Michael Wonder on 27 Jan 2024
ICER publishes evidence report on treatment for schizophrenia
25 January 2024 - KarXT has a novel mechanism of action, but there are significant uncertainties regarding long term efficacy and safety; KarXT would achieve common thresholds for cost effectiveness if priced between $16,000 - $20,000/year.
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of xanomeline tartrate/trospium chloride (KarXT, Karuna Therapeutics) for the treatment of schizophrenia.
